Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Cubana de Salud Pública
versión On-line ISSN 1561-3127
Resumen
RUIZ MARTIN LEYES, Fernando Javier et al. Resistance of Mycobacterium tuberculosis to quinolone and injectable drugs in Atlántico department, 2013-2016. Rev Cubana Salud Pública [online]. 2021, vol.47, n.2 Epub 30-Jun-2021. ISSN 1561-3127.
Introduction:
In Atlántico department, resistance studies of Mycobacterium tuberculosis have been limited to second-line drugs.
Objective:
Determine prevalence of resistance to amikacin, kanamycin, capreomycin and ofloxacin in cases of tuberculosis resistant to isoniazid, rifampicin or both, in the period 2013 to 2016 in Atlántico department.
Methods:
Cross-sectional study of 194 isolations resistant to isoniazid, rifampicin or both, by Genotype MTBDR plus version 2 methodology, that were sent to the National Institute of Health from 2013 to 2016 to be confirmed and processed for second-line drugs. The resistance ratio was made according to sociodemographic, clinical and public health surveillance variables.
Results:
The common comorbilities found were malnutrition with 18.56%, followed by concomitant HIV-tuberculosis infection with 13.40%. Ofloxacin in non-treated cases achieved the highest overall resistance with 1.50% (95% CI 0.18-5.33). In those previously treated, global resistance to capreomycin was 8.10% (95% CI 2.7-17.8). In the ones resistant to rifampicin, one case was extensively resistant and two cases were resistant in multi-drugs resistant.
Conclusions:
Low resistance to fluoroquinolones and injectable drugs was found in non-treated patients who were resistant to isoniazid, rifampicin or both, showing that it is not yet a major problem in Atlántico department. Its follow-up should be complemented with good physical and psychological management and a strengthened health team that acts promptly and helps the patient adherence to treatments.
Palabras clave : fluoroquinolones; isoniazid; rifampicin; drug-resistant tuberculosis; extensively drug-resistant tuberculosis.